Literature DB >> 10913626

Functional Fv fragment of an antibody specific for CD28: Fv-mediated co-stimulation of T cells.

S Takemura1, R Asano, K Tsumoto, T Arai, N Sakurai, H Kodama, H Yoshida, Y Katayose, M Suzuki, S Matsuno, T Kudo, I Kumagai.   

Abstract

The most predominant co-stimulation pathway, which is critical for T cell activation and proliferation, is the CD28-B7 pathway. The anti-CD28 monoclonal antibody (mAb) also provides a co-stimulatory signal to T cells. In order to construct a functional Fv fragment (complex of VH and VL domains) of anti-CD28 antibody using a bacterial expression system, cDNA encoding the variable regions of immunoglobulin from 15E8 hybridoma cells was cloned and expressed in Escherichia coli. The Fv fragment was obtained as a soluble protein from the periplasmic fraction and showed a binding pattern similar to parental IgG. The Fv fragment induced proliferation of peripheral blood mononuclear cells in the presence of anti-CD3 or anti-CD2 mAb and enhanced anti-tumor activity of anti-MUC1x(anti)-CD3 bispecific antibody when tested with lymphokine-activated killer cells with T cell phenotype. Thus, the anti-CD28 Fv fragment will be promising not only for the study of co-stimulation, but also for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913626     DOI: 10.1016/s0014-5793(00)01741-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  Expression, purification, and characterization of recombinant fibulin-5 in a prokaryote expression system.

Authors:  Myoung Seok Jeong; Chang Soo Kang; Yeon Soo Han; In Seok Bang
Journal:  J Microbiol       Date:  2010-11-03       Impact factor: 3.422

2.  Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life.

Authors:  Ryutaro Asano; Noriaki Koyama; Yasuyo Hagiwara; Yosuke Masakari; Ryota Orimo; Kyoko Arai; Hiromi Ogata; Shozo Furumoto; Mitsuo Umetsu; Izumi Kumagai
Journal:  FEBS Open Bio       Date:  2016-05-16       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.